Todd Waldman

13.8k total citations · 5 hit papers
66 papers, 10.9k citations indexed

About

Todd Waldman is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Todd Waldman has authored 66 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 26 papers in Oncology and 11 papers in Genetics. Recurrent topics in Todd Waldman's work include Cancer-related Molecular Pathways (20 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and Genomics and Chromatin Dynamics (12 papers). Todd Waldman is often cited by papers focused on Cancer-related Molecular Pathways (20 papers), PI3K/AKT/mTOR signaling in cancer (15 papers) and Genomics and Chromatin Dynamics (12 papers). Todd Waldman collaborates with scholars based in United States, United Kingdom and Austria. Todd Waldman's co-authors include Bert Vogelstein, Kenneth W. Kinzler, Christoph Lengauer, Fred Bunz, K. W. Kinzler, Jung-Sik Kim, Steven Zhou, Jeremy Brown, Annie Dutriaux and John M. Sedivy and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Todd Waldman

66 papers receiving 10.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Requirement for p53 and p21 to Sustain G ₂ Arrest After DNA Damage

1998 2.5k citations Todd Waldman et al. Science profile →
p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

1995 1.1k citations Todd Waldman et al. PubMed profile →
Disruption of p53 in human cancer cells alters the responses to therapeutic agents

1999 883 citations Todd Waldman et al. profile →
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21

1996 637 citations Todd Waldman et al. profile →
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.

1995 525 citations Todd Waldman et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Todd Waldman United States	39	8.0k	5.7k	2.0k	1.2k	997	66	10.9k
Elinor Ng Eaton United States	16	9.4k 1.2×	8.1k 1.4×	3.6k 1.8×	1.4k 1.1×	1.2k 1.2×	19	15.9k
Ygal Haupt Australia	48	9.0k 1.1×	7.1k 1.2×	2.2k 1.1×	903 0.8×	973 1.0×	111	12.4k
Gerard P. Zambetti United States	58	10.6k 1.3×	8.0k 1.4×	3.2k 1.6×	1.1k 0.9×	758 0.8×	133	15.7k
Gary E. Gallick United States	67	7.7k 1.0×	6.0k 1.0×	2.9k 1.5×	1.3k 1.1×	2.0k 2.0×	202	13.7k
Stephen N. Jones United States	50	10.6k 1.3×	5.9k 1.0×	2.4k 1.2×	1.1k 0.9×	467 0.5×	114	13.2k
Khandan Keyomarsi United States	51	6.7k 0.8×	5.5k 1.0×	2.2k 1.1×	1.7k 1.5×	1.7k 1.7×	158	10.7k
Klas G. Wiman Sweden	67	9.3k 1.2×	7.0k 1.2×	2.3k 1.2×	791 0.7×	961 1.0×	179	14.1k
Christophe Ginestier France	43	7.2k 0.9×	8.2k 1.4×	4.3k 2.2×	948 0.8×	1.3k 1.3×	94	12.8k
Jiandong Chen United States	57	8.3k 1.0×	6.3k 1.1×	1.5k 0.8×	1.2k 1.0×	634 0.6×	127	11.4k
Emma Lees United States	46	7.2k 0.9×	4.9k 0.9×	1.1k 0.6×	1.8k 1.5×	647 0.6×	73	9.8k

Countries citing papers authored by Todd Waldman

Since Specialization

Citations

This map shows the geographic impact of Todd Waldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Waldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Waldman more than expected).

Fields of papers citing papers by Todd Waldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Waldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Waldman. The network helps show where Todd Waldman may publish in the future.

Co-authorship network of co-authors of Todd Waldman

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Waldman. A scholar is included among the top collaborators of Todd Waldman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Waldman. Todd Waldman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kwon, Juntae, Haiyang Wang, Kerrie B. Bouker, et al.. (2022). USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model. Oncogene. 41(13). 1974–1985. 12 indexed citations

He, Xiaoyuan, Jung-Sik Kim, Laura A. Díaz-Martínez, et al.. (2021). USP13 interacts with cohesin and regulates its ubiquitination in human cells. Journal of Biological Chemistry. 296. 100194–100194. 7 indexed citations

Waldman, Todd. (2020). Emerging themes in cohesin cancer biology. Nature reviews. Cancer. 20(9). 504–515. 61 indexed citations

Kim, Jung-Sik, Xiaoyuan He, Jie Liu, et al.. (2019). Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression. Journal of Biological Chemistry. 294(22). 8760–8772. 30 indexed citations

Prip, Frederik, Brent T. Harris, David A. Solomon, et al.. (2018). STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 24(17). 4145–4153. 24 indexed citations

Kim, Jung-Sik, Xiaoyuan He, Bernardo Orr, et al.. (2016). Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2. PLoS Genetics. 12(2). e1005865–e1005865. 38 indexed citations

Walia, Vijay, Todd D. Prickett, Jung-Sik Kim, et al.. (2014). Mutational and Functional Analysis of the Tumor-Suppressor PTPRD in Human Melanoma. Human Mutation. 35(11). n/a–n/a. 25 indexed citations

Bailey, Melanie L., Nigel J. O’Neil, Derek M. van Pel, et al.. (2013). Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition. Molecular Cancer Therapeutics. 13(3). 724–732. 58 indexed citations

Nicolaides, Theodore, Huifang Li, David A. Solomon, et al.. (2011). Targeted Therapy for BRAFV600E Malignant Astrocytoma. Clinical Cancer Research. 17(24). 7595–7604. 113 indexed citations

10.

Solomon, David A., Taeyeon Kim, Laura A. Díaz-Martínez, et al.. (2011). Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer. Science. 333(6045). 1039–1043. 311 indexed citations

11.

Nguyen, Quang‐Dé, Meg Perumal, Todd Waldman, & Eric O. Aboagye. (2011). Glucose Metabolism Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography Is Independent of PTEN/AKT Status in Human Colon Carcinoma Cells. Translational Oncology. 4(4). 241–248. 19 indexed citations

12.

Michaud, Karine, David A. Solomon, Eric K. Oermann, et al.. (2010). Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts. Cancer Research. 70(8). 3228–3238. 254 indexed citations

13.

Solomon, David A., Jung-Sik Kim, Habtom W. Ressom, et al.. (2009). Sample Type Bias in the Analysis of Cancer Genomes. Cancer Research. 69(14). 5630–5633. 26 indexed citations

14.

Vítolo, Michele, Michele B. Weiss, Todd Waldman, et al.. (2009). Deletion of PTEN Promotes Tumorigenic Signaling, Resistance to Anoikis, and Altered Response to Chemotherapeutic Agents in Human Mammary Epithelial Cells. Cancer Research. 69(21). 8275–8283. 74 indexed citations

15.

Solomon, David A., Jung-Sik Kim, Habtom W. Ressom, et al.. (2008). Identification of p18INK4c as a Tumor Suppressor Gene in Glioblastoma Multiforme. Cancer Research. 68(8). 2564–2569. 38 indexed citations

16.

Solomon, David A., Jung-Sik Kim, Julia C. Cronin, et al.. (2008). Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma. Cancer Research. 68(24). 10300–10306. 102 indexed citations

17.

Solomon, David A., Jung-Sik Kim, Walter C. Jean, & Todd Waldman. (2008). Conspirators in a Capital Crime: Co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in Glioblastoma Multiforme. Cancer Research. 68(21). 8657–8660. 30 indexed citations

18.

Bonifant, Challice L., Jung‐Sik Kim, & Todd Waldman. (2007). NHERFs, NEP, MAGUKs, and more: Interactions that regulate PTEN. Journal of Cellular Biochemistry. 102(4). 878–885. 19 indexed citations

19.

Kim, Jung-Sik, Carolyn Lee, Challice L. Bonifant, Habtom W. Ressom, & Todd Waldman. (2006). Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA. Molecular and Cellular Biology. 27(2). 662–677. 128 indexed citations

20.

Kim, Jung-Sik, et al.. (2002). Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors.. PubMed. 1(14). 1355–9. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact